CTRI/2021/07/034906招募中4 期
A Post Marketing Surveillance (PMS) Study for VPRIV�® (velaglucerase alfa) in India - SHP669-406_VPRIV�® (velaglucerase alfa) - India
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Patients with Gaucher disease prescribed VPRIV according to the investigators judgment and current Indian PI are eligible for this study. Patient or legally authorized representative must provide written informed consent to participate
排除标准
- •Patients will be excluded from this study if the patient met any of the contraindications included
- •in the current Indian PI for VPRIV
研究者
相似试验
已完成
4 期
A study to assess the safety and tolerability of VELNEZ nasal pack after nasal surgeryCTRI/2018/04/013227Datt Mediproducts Pvt Ltd37
已完成
4 期
A study to assess the safety and tolerability of VELNEZ nasal pack after surgery of noseCTRI/2018/12/016535Datt Mediproducts Pvt Ltd40
已完成
4 期
A study (PMS) to check and assess the safety and tolerability of a biodegradable nasal dressing (VELNEZ) after nose surgery.CTRI/2021/09/036437Datt Mediproducts Pvt Ltd20
进行中（未招募）
4 期
A prospective, Post Marketing Surveillance study of omalizumab in Chronic Spontaneous UrticariaCTRI/2015/10/006247ovartis Healthcare Private Limited
已完成
不适用
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in IndiaGaucher DiseaseNCT04429984Shire21